Publication: International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: Correlates of high Ad5 titers and implications for potential HIV vaccine trials
Issued Date
2010-01-22
Resource Type
ISSN
0264410X
Other identifier(s)
2-s2.0-73949160519
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Vaccine. Vol.28, No.4 (2010), 950-957
Suggested Citation
T. Christopher Mast, Lisa Kierstead, Swati B. Gupta, Alexander A. Nikas, Esper G. Kallas, Vladimir Novitsky, Bernard Mbewe, Punee Pitisuttithum, Mauro Schechter, Eftyhia Vardas, Nathan D. Wolfe, Miguel Aste-Amezaga, Danilo R. Casimiro, Paul Coplan, Walter L. Straus, John W. Shiver International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: Correlates of high Ad5 titers and implications for potential HIV vaccine trials. Vaccine. Vol.28, No.4 (2010), 950-957. doi:10.1016/j.vaccine.2009.10.145 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/28801
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: Correlates of high Ad5 titers and implications for potential HIV vaccine trials
Abstract
Replication-defective adenoviruses have been utilized as candidate HIV vaccine vectors. Few studies have described the international epidemiology of pre-existing immunity to adenoviruses. We enrolled 1904 participants in a cross-sectional serological survey at seven sites in Africa, Brazil, and Thailand to assess neutralizing antibodies (NA) for adenovirus types Ad5, Ad6, Ad26 and Ad36. Clinical trial samples were used to assess NA titers from the US and Europe. The proportions of participants that were negative were 14.8% (Ad5), 31.5% (Ad6); 41.2% (Ad26) and 53.6% (Ad36). Adenovirus NA titers varied by geographic location and were higher in non-US and non-European settings, especially Thailand. In multivariate logistic regression analysis, geographic setting (non-US and non-European settings) was statistically significantly associated with having higher Ad5 titers; participants from Thailand had the highest odds of having high Ad5 titers (adjusted OR = 3.53, 95% CI: 2.24, 5.57). Regardless of location, titers of Ad5NA were the highest and Ad36 NA were the lowest. Coincident Ad5/6 titers were lower than either Ad5 or Ad6 titers alone. Understanding pre-existing immunity to candidate vaccine vectors may contribute to the evaluation of vaccines in international populations. © 2009.